NCT07361562 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07361562
Title	A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Cogent Biosciences, Inc.
Indications	breast cancer Advanced Solid Tumor lung non-small cell carcinoma
Therapies	CGT4255
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
NEXT Oncology Texas	RECRUITING	Austin	Texas	78758	United States	Details
NEXT Oncology Virginia	RECRUITING	Fairfax	Virginia	22031	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07361562Clinical Trial Detail